VAF less than 1% by best response on treatment
Matrix . | Observed outcome by best response on treatment . | Risk difference in comparison with patients with best response of NR . | |||||
|---|---|---|---|---|---|---|---|
| CR . | CRh . | CRL . | NR . | CR vs NR . | CRh vs NR . | CRL vs NR . | |
| Marrow subgroup, n | 90 | 26 | 58 | 272 | |||
| Marrow VAF <1%, % (95% CI) | 34.4%∗ (24.7-45.2) | 26.9%∗ (11.6-47.8) | 8.6% (2.9-19.0) | 3.3% (1.5-6.2) | 31.1 (21.1-41.2) | 23.6 (6.4-40.8) | 5.3 (–2.2 to 12.8) |
| Peripheral blood subgroup, n | 127 | 32 | 57 | 331 | |||
| Peripheral blood VAF <1%, % (95% CI) | 40.2%∗ (31.6-49.2) | 21.9%∗ (9.3-40.0) | 7.0% (1.9-17.0) | 4.5% (2.6-7.4) | 35.6 (26.8-44.4) | 17.3 (2.8-31.8) | 2.5 (–4.5 to 9.5) |
Matrix . | Observed outcome by best response on treatment . | Risk difference in comparison with patients with best response of NR . | |||||
|---|---|---|---|---|---|---|---|
| CR . | CRh . | CRL . | NR . | CR vs NR . | CRh vs NR . | CRL vs NR . | |
| Marrow subgroup, n | 90 | 26 | 58 | 272 | |||
| Marrow VAF <1%, % (95% CI) | 34.4%∗ (24.7-45.2) | 26.9%∗ (11.6-47.8) | 8.6% (2.9-19.0) | 3.3% (1.5-6.2) | 31.1 (21.1-41.2) | 23.6 (6.4-40.8) | 5.3 (–2.2 to 12.8) |
| Peripheral blood subgroup, n | 127 | 32 | 57 | 331 | |||
| Peripheral blood VAF <1%, % (95% CI) | 40.2%∗ (31.6-49.2) | 21.9%∗ (9.3-40.0) | 7.0% (1.9-17.0) | 4.5% (2.6-7.4) | 35.6 (26.8-44.4) | 17.3 (2.8-31.8) | 2.5 (–4.5 to 9.5) |
See supplemental Table 2 for details.
%, percentage of patients with the VAF <1% on treatment; n, number of patients with the disease response listed in the column header in the marrow or peripheral blood cohort tested for VAF; VAF, variant allele frequency for the allele identified by the companion diagnostic assay at study baseline.
P < .01 for comparison with NR by logistic regression adjusting for drug and baseline transfusion dependence status.